High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Profitability: Very strong Profitability. One year profit margin are 26%.
Balance Sheet: Strong Balance Sheet.
Dividend: Dividend paying stock. Dividend yield of 2.63%.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Size: Market Cap wise it is among the top 20% companies of india.
Smart Money: Smart money has been increasing their position in the stock.
Past Returns: In past three years, the stock has provided 16% return compared to 8.1% by NIFTY 50.
Technicals: SharesGuru indicator is Bearish.
Momentum: Stock is suffering a negative price momentum. Stock is down -8.4% in last 30 days.
Valuation | |
|---|---|
| Market Cap | 36.68 kCr |
| Price/Earnings (Trailing) | 36.02 |
| Price/Sales (Trailing) | 9.25 |
| EV/EBITDA | 24.12 |
| Price/Free Cashflow | 43.26 |
| MarketCap/EBT | 26.09 |
| Enterprise Value | 35.58 kCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 3.97 kCr |
| Rev. Growth (Yr) | 1.6% |
| Earnings (TTM) | 1.04 kCr |
| Earnings Growth (Yr) | 5.7% |
Profitability | |
|---|---|
| Operating Margin | 35% |
| EBT Margin | 35% |
| Return on Equity | 45.34% |
| Return on Assets | 23.96% |
| Free Cashflow Yield | 2.31% |
Growth & Returns | |
|---|---|
| Price Change 1W | -4.2% |
| Price Change 1M | -8.4% |
| Price Change 6M | -14.9% |
| Price Change 1Y | -36.7% |
| 3Y Cumulative Return | 16% |
| 5Y Cumulative Return | 8.4% |
| 7Y Cumulative Return | 7.9% |
| 10Y Cumulative Return | -4.7% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | 396.98 Cr |
| Cash Flow from Operations (TTM) | 903.3 Cr |
| Cash Flow from Financing (TTM) | -737.08 Cr |
| Cash & Equivalents | 1.1 kCr |
| Free Cash Flow (TTM) | 848.02 Cr |
| Free Cash Flow/Share (TTM) | 50.06 |
Balance Sheet | |
|---|---|
| Total Assets | 4.32 kCr |
| Total Liabilities | 2.04 kCr |
| Shareholder Equity | 2.28 kCr |
| Current Assets | 3.78 kCr |
| Current Liabilities | 1.78 kCr |
| Net PPE | 273.51 Cr |
| Inventory | 457.55 Cr |
| Goodwill | 0.00 |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.00 |
| Debt/Equity | 0.00 |
| Interest Coverage | 514.02 |
| Interest/Cashflow Ops | 331.88 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 57 |
| Dividend Yield | 2.63% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
Profitability: Very strong Profitability. One year profit margin are 26%.
Balance Sheet: Strong Balance Sheet.
Dividend: Dividend paying stock. Dividend yield of 2.63%.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Size: Market Cap wise it is among the top 20% companies of india.
Smart Money: Smart money has been increasing their position in the stock.
Past Returns: In past three years, the stock has provided 16% return compared to 8.1% by NIFTY 50.
Technicals: SharesGuru indicator is Bearish.
Momentum: Stock is suffering a negative price momentum. Stock is down -8.4% in last 30 days.
Investor Care | |
|---|---|
| Dividend Yield | 2.63% |
| Dividend/Share (TTM) | 57 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 60.11 |
Financial Health | |
|---|---|
| Current Ratio | 2.13 |
| Debt/Equity | 0.00 |
Technical Indicators | |
|---|---|
| RSI (14d) | 8.33 |
| RSI (5d) | 0.00 |
| RSI (21d) | 34.97 |
| MACD Signal | Sell |
| Stochastic Oscillator Signal | Buy |
| SharesGuru Signal | Sell |
| RSI Signal | Buy |
| RSI5 Signal | Buy |
| RSI21 Signal | Hold |
| SMA 5 Signal | Sell |
| SMA 10 Signal | Sell |
| SMA 20 Signal | Sell |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
Summary of GlaxoSmithkline Pharmaceuticals's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Understand GlaxoSmithkline Pharmaceuticals ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| GLAXO GROUP LIMITED | 35.99% |
| GLAXOSMITHKLINE PTE LIMITED | 28.1% |
| ESKAYLAB LIMITED | 6.94% |
| BURROUGHS WELLCOME INTERNATIONAL LIMITED | 3.97% |
| FOREIGN INSTITUTIONAL INVESTORS | 0% |
| FOREIGN BANK | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of GlaxoSmithkline Pharmaceuticals against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 4.27 LCr | 60.43 kCr | -2.20% | +6.90% | 37.24 | 7.07 | - | - |
| DIVISLAB | Divi's Lab | 1.75 LCr | 11.07 kCr | -0.80% | -0.30% | 68.18 | 15.82 | - | - |
| CIPLA | Cipla | 1.13 LCr | 29.04 kCr | +4.90% | -5.00% | 29.16 | 3.9 | - | - |
| DRREDDY | Dr. Reddy's Lab | 1.06 LCr | 35.06 kCr | -0.20% | +1.30% | 25.17 | 3.02 | - | - |
| LUPIN | Lupin | 1.03 LCr | 28.38 kCr | -3.90% | +15.80% | 19.29 | 3.63 | - | - |
| AUROPHARMA | Aurobindo Pharma | 85.03 kCr | 34.18 kCr | +2.50% | +28.60% | 24.26 | 2.49 | - | - |
| ABBOTINDIA | Abbott India | 59.24 kCr | 7.11 kCr | +2.00% | -17.60% | 35.97 | 8.46 | - | - |
| PFIZER | Pfizer | 20.22 kCr | 2.71 kCr | -5.90% | -23.20% | 27.98 | 7.47 | - | - |
| SANOFI | Sanofi India | 7.32 kCr | 1.79 kCr | -6.60% | -48.60% | 23.64 | 4.08 | - | - |
Comprehensive comparison against sector averages
GLAXO metrics compared to Pharmaceuticals
| Category | GLAXO | Pharmaceuticals |
|---|---|---|
| PE | 36.23 | 35.90 |
| PS | 9.30 | 4.95 |
| Growth | 1.8 % | 10.7 % |
GlaxoSmithkline Pharmaceuticals is a prominent pharmaceuticals company based in India, with the stock ticker GLAXO.
The company has a substantial market cap of Rs. 48,245.1 Crores and specializes in manufacturing, distributing, and trading a wide array of pharmaceutical products both domestically and internationally.
GlaxoSmithkline Pharmaceuticals is known for its diverse portfolio which includes:
Vaccines:
Specialty Medicines:
General Medicines:
The company is also involved in developing products aimed at treating infectious diseases, HIV, oncology, and immunology.
Originally named SmithKline Beecham Pharmaceuticals India Ltd, it rebranded to GlaxoSmithKline Pharmaceuticals Limited in 2001. Incorporated in 1924, the company is headquartered in Mumbai, India.
In terms of financial performance, GlaxoSmithkline Pharmaceuticals reported a trailing 12 months revenue of Rs. 3,839.7 Crores and a profit of Rs. 859.2 Crores in the last four quarters. The company has experienced a 9.2% revenue growth over the past three years and distributes dividends to its investors, boasting a dividend yield of 1.54% per year, with a recent dividend payment of Rs. 44 per share.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
GLAXO vs Pharmaceuticals (2021 - 2026)